![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Amgen’s Repatha Pushtronex System
FDA Approves Amgen’s Repatha Pushtronex System
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
The FDA has granted approval to Amgen’s monthly, single-dose Repatha Pushtronex system.
The device is hands-free and delivers 420 mg of the PCSK9 inhibitor Repatha in a single dose. The treatment was approved by the FDA in August 2015 as the second PCSK9 inhibitor, days behind Sanofi and Regeneron’s Praluent.
The system’s development — which is based on the SmartDose technology platform — stems from a joint effort between Amgen and West Pharmaceutical Services. — Anisa Jibrell
Upcoming Events
-
21Oct